Last reviewed · How we verify
SHR-1802
At a glance
| Generic name | SHR-1802 |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of SHR-1802 in Patients With Advanced Solid Tumor (PHASE2)
- A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR-1802 CI brief — competitive landscape report
- SHR-1802 updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI